Sign in →

Test ID PVLE Paraneoplastic Vision Loss Evaluation, Serum

Necessary Information

Provide the following information:

-Relevant clinical information

-Ordering provider name, phone number, mailing address, and e-mail address

Specimen Required

Patient Preparation:

1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication.

2. This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 4 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Useful For

Evaluating patients with rapidly progressive vision loss where a paraneoplastic cause for vision loss (retinopathy or optic neuritis with other findings [eg, retinitis] is suspected)


Evaluating patients with small-cell carcinoma who develop vision loss

Profile Information

Test ID Reporting Name Available Separately Always Performed
PVLEI Paraneoplas Vision Loss Interp, S No Yes
RCVBS Recoverin Immunoblot, S Yes Yes

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
CRMWS CRMP-5-IgG Western Blot, S Yes No
CRMTS CRMP-5-IgG Titer, S No No

Testing Algorithm

If the indirect immunofluorescence assay (IFA) patterns suggest collapsin response-mediator protein-5 (CRMP-5) antibody, then CRMP-5 IFA titer and CRMP-5 Western blot will be performed at an additional charge.

Method Name

PVLEI: Medical Interpretation

CRMTS, CRMS: Indirect Immunofluorescence Assay (IFA)

CRMWS: Western Blot (WB)

RCVBS: Immunoblot (IB)

Reporting Name

Paraneoplastic Vision Loss Eval, S

Specimen Type


Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reference Values











Titers lower than 1:240 are detectable by recombinant CRMP-5 Western blot analysis. CRMP-5 Western blot analysis will be done on request on stored serum (held 4 weeks). This supplemental testing is recommended in cases of chorea, vision loss, cranial neuropathy, and myelopathy. Call 1-800-533-1710 to request CRMP-5 Western blot. Neuron-restricted patterns of IgG staining that do not fulfill criteria for CRMP-5-IgG may be reported as "unclassified antineuronal IgG." Complex patterns that include non-neuronal elements may be reported as "uninterpretable."

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255 x1

84182 x1

84182 CRMWS (if appropriate)

86256 CRMTS (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PVLE Paraneoplastic Vision Loss Eval, S In Process


Result ID Test Result Name Result LOINC Value
83077 CRMP-5-IgG, S 94815-8
610009 Recoverin Immunoblot, S 83003-4
607411 Paraneoplas Vision Loss Interp, S In Process
618908 IFA Notes 48767-8


If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.

Day(s) Performed

Profile tests: Monday through Sunday; Reflex tests: Varies

Report Available

8 to 10 days